<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454662</url>
  </required_header>
  <id_info>
    <org_study_id>31-JAN-2007</org_study_id>
    <secondary_id>COLM001</secondary_id>
    <nct_id>NCT00454662</nct_id>
  </id_info>
  <brief_title>Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)</brief_title>
  <official_title>Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>COLM Study Research Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>COLM Study Research Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate which combination therapy is more effective in
      reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive
      patients: AT1 subtype angiotensin II receptor antagonist/calcium channel blocker or AT1
      subtype angiotensin II receptor antagonist/low dose diuretic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, antihypertensive combination therapies have been recommended by various guidelines
      because of their additive effects. Combination therapies of AT1 subtype angiotensin II
      receptor antagonist and calcium channel blocker or low dose diuretic have shown
      pharmacological benefit. However, reduction of cardiovascular events and safety profile of
      these combination therapies under same level of antihypertensive target have not been
      investigated yet.

      In this study, primary objective is to compare two combination therapies when
      antihypertensive target is 140/90mmHg in elderly hypertensive patients with high
      cardiovascular risk.

      Further study details as provided by COLM-Study data center

      Primary Outcomes: A composite of fatal and non-fatal cardiovascular events: Sudden death
      (death of endogenous origin within 24 hours after acute onset); Cerebrovascular events (new
      occurrence or recurrence of a cerebral infarction, cerebral hemorrhage, subarachnoid
      hemorrhage or transient ischemic attack); Coronary events (new occurrence or recurrence of a
      myocardial infarction, coronary revascularization[PCI or CABG], hospitalization for angina
      pectoris, hospitalization for heart failure); Renal dysfunction (doubling of serum creatinine
      and creatinine ≥2.0 mg/dl, end stage renal disease) Secondary Outcomes: All deaths; Death
      from cardiovascular events; Effects on glucose metabolism(fasting plasma glucose,
      postprandial glucose, new onset of diabetes mellitus); Incidence of primary outcomes events;
      New occurrence of atrial fibrillation; Safety; Proportion of the subjects who withdrew from
      the allocated treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of following events: Sudden death, Cerebrovascular events, Coronary events, Renal dysfunction</measure>
    <time_frame>3 to 4.5 years (duration of planned treatment phase)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All deaths, Death from cardiovascular events, Glucose metabolism, Incidence of primary outcomes events, New onset of atrial fibrillation, Safety, Withdrawal rate</measure>
    <time_frame>3 to 4.5 years (duration of planned treatment phase)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5141</enrollment>
  <condition>Hypertension</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>olmesartan medoxomil, Calcium channel blockers (amlodipine, azelnidipine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AT1 subtype angiotensin II receptor antagonist/low dose diuretic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil / amlodipine or azelnidipine</intervention_name>
    <description>AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil / low dose thiazide type drug</intervention_name>
    <description>AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients aged 65 years or older, and less than 85 years (at the time of informed
             consent), regardless of sex

          -  Systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg in
             a sitting position on two consecutive measurements at clinic during use of 1 or more
             antihypertensive medications.

          -  Systolic blood pressure (SBP) ≥160 mmHg or diastolic blood pressure (DBP) ≥100 mmHg in
             a sitting position on two consecutive measurements at clinic without antihypertensive
             medication.

          -  Require at least one of the following medical history or risk factors

          -  Medical history

               -  Cerebrovascular accident: cerebral infarction, brain hemorrhage, subarachnoid
                  hemorrhage（6 months or more prior to registration）

               -  Myocardial infarction, coronary revascularization (PCI or CABG) （6 months or more
                  prior to registration）

               -  Angina pectoris (except for the patients having history of hospitalization within
                  6 months prior to registration)

          -  Risk factors

               -  Male

               -  Current diabetes mellitus, fasting glucose ≥ 110mg/dL or postprandial glucose ≥
                  140mg/dl

               -  Hypercholesterolemia (Total cholesterol ≥ 260mg/dL)

               -  Low HDL cholesterolemia (HDL-C ＜40mg/dL)

               -  Microalbuminuria (albumin/cr ≥ 30mg/gCr) or proteinuria (protein ≥ 1＋)

               -  Left ventricular hypertrophy (ST-T change in the ECG and SV1＋RV5 ≥ 35mm, or left
                  ventricular mass index: male ≥ 125 g/m2, female ≥ 110 g/m2)

        Exclusion Criteria:

          -  Secondary hypertension or malignant hypertension

          -  History of cerebrovascular accident (including TIA) or myocardial infarction within 6
             months before registration

          -  Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
             done within 6 months before registration or scheduled

          -  History of hospitalization for angina pectoris or heart failure within 6 months before
             registration

          -  Severe heart failure (New York Heart Association [NYHA] functional class III or more
             severe)

          -  Complications of atrial fibrillation, atrial flutter or severe arrhythmia

          -  Severe hepatic or renal dysfunction (including current treatment of dialysis or renal
             dysfunction with serum creatinine ≥ 2.0mg/dL)

          -  Not appropriate for change to the study drugs from current therapy for concurrent
             disease including coronary diseases (i.e. calcium channel blockers, diuretics, etc)

          -  History of serious side effect from study drugs (AT1 subtype angiotensin II receptor
             antagonist, calcium channel blocker, diuretic)

          -  Life threatening condition (malignant tumor, etc)

          -  Not suited to be study subject judged by a study physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshio Ogihara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Emeritus Professor Osaka University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takao Saruta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Emeritus Professor Keio University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>COLM-Study Data Center</name>
      <address>
        <city>Kamiyacho MT Bld.14F, 4-3-20 Toranomon Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2007</study_first_submitted>
  <study_first_submitted_qc>March 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2007</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elderly</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
  <keyword>Calcium Channel Blockers</keyword>
  <keyword>Diuretics</keyword>
  <keyword>Combination Drug Therapy</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

